About 96% of all 15+ population in the country have received at least one Covid-19 vaccine dose while about 83% of 15+ population has received both the doses
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
An upgraded, state-of-the-art integrated app, helps easy discovery of expert surgeons for convenient in-clinic or online consultation
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
Subscribe To Our Newsletter & Stay Updated
